Liminatus Pharma, Inc.

LIMN Nasdaq SEC CIK 1971387
Follow Liminatus Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$1.4M −1342.2% vs same quarter last year
EPS, diluted −$0.03
Operating cash flow −$970K +89% vs same quarter last year
Operating income −$1.4M −23.3% vs same quarter last year
Net income by quarter
−$601.4K
−$229.8K
−$327.5K
$113.3K
−$1.8M
−$8.2M
−$1.1M
−$1.4M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing